[[PAGE:1]]

DECISION LOGIC

Step 1: confirm EGFR activating mutation. Step 2: if first-line metastatic NSCLC, consider the authorised product when within approved EU label criteria.

[[PAGE:2]]

EXCLUSIONS

Do not route adjuvant-only pathways into first-line metastatic approval logic.